scholarly journals Case Report: Priapism as the clinical presentation of chronic myeloid leukemia in accordance with reports created during last twenty years: a case report and literature review

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 571
Author(s):  
Siprianus Ugroseno Yudho Bintoro ◽  
Pradana Zaky Romadhon ◽  
Satriyo Dwi Suryantoro ◽  
Rusdi Zakki Aminy ◽  
Choirina Windradi ◽  
...  
Keyword(s):  
Case Report ◽  
Early Intervention ◽  
Chronic Myeloid Leukemia ◽  
Literature Review ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Clinical Presentation ◽  
Kinase Inhibitor ◽  
The Past ◽  
Blood Aspiration

Priapism in chronic myeloid leukemia (CML) appears to be an infrequent manifestation as well as a crucial emergency. Here, we report an 18-year-old male presenting with a persistent erection of penis for 20 days. We evaluate and compare the reported cases during the past 20 years discussing the management of CML patients experiencing priapism. Cytoreductive therapy followed by leukapheresis, the administration of tyrosine kinase inhibitor, and intra-cavernosal blood aspiration may resolve the symptoms of priapism. Early intervention for cytoreduction and aspiration are the pivotal keys to successfully impeding the complications.

scholarly journals Case Report: Priapism as The Clinical Presenting Feature of Chronic Myeloid Leukemia: Case Report and 20-Year Literature Review

F1000Research ◽  
2022 ◽  
Vol 10 ◽  
pp. 571
Author(s):  
Siprianus Ugroseno Yudho Bintoro ◽  
Pradana Zaky Romadhon ◽  
Satriyo Dwi Suryantoro ◽  
Rusdi Zakki Aminy ◽  
Choirina Windradi ◽  
...  
Keyword(s):  
Case Report ◽  
Early Intervention ◽  
Chronic Myeloid Leukemia ◽  
Literature Review ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Blood Aspiration

Priapism in chronic myeloid leukemia (CML) appears to be an infrequent manifestation as well as a crucial emergency. Here, we report an 18-year-old male presenting with a persistent erection of the penis for 20 days. We evaluated and compared the reported cases within 20 years discussing the management of priapism in CML. Cytoreductive therapy followed by leukapheresis, the administration of tyrosine kinase inhibitor, and intra-cavernosal blood aspiration may resolve the symptoms of priapism. Early intervention for cytoreduction and aspiration are the pivotal keys to successfully impeding the complications.

scholarly journals Tyrosine kinase inhibitor and rituximab-CHOP treatment for concurrent chronic myeloid leukemia and non-Hodgkin lymphoma: a case report

2017 ◽  
Vol 5 (12) ◽  
pp. 2047-2050
Author(s):  
Yuki Takeyasu ◽  
Atsushi Satake ◽  
Yoshiko Azuma ◽  
Yukie Tsubokura ◽  
Hideaki Yoshimura ◽  
...  
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Hodgkin Lymphoma ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Non Hodgkin Lymphoma

scholarly journals Pancytopenia during tyrosine kinase inhibitor treatment – coexistence of chronic myeloid leukemia and visceral leishmaniasis: a case report

2016 ◽  
Vol 10 (1) ◽  
Author(s):  
Acy Quixada ◽  
Pedro Aurio Maia Filho ◽  
Tarcísio Paulo Almeida Filho ◽  
Fernando Barroso Duarte ◽  
Caroline Aquino Moreira-Nunes ◽  
...  
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Visceral Leishmaniasis ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Inhibitor Treatment

Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report

2015 ◽  
Vol 16 (7) ◽  
pp. 677-679 ◽  
Author(s):  
Geoffroy Venton ◽  
Julien Colle ◽  
Cedric Mercier ◽  
Raphaelle Fanciullino ◽  
Joseph Ciccolini ◽  
...  
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Third Generation ◽  
T315i Mutation

scholarly journals Efficacy of nilotinib in second line in an elderly patient with CML, suboptimal response and multiple comorbidities

2015 ◽  
Vol 7 (1S) ◽  
pp. 25-29
Author(s):  
Carmen Tomaselli
Keyword(s):  
Elderly Patient ◽  
Heart Disease ◽  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Clinical Case ◽  
Kinase Inhibitor ◽  
Cytogenetic Response ◽  
Second Line

In this case report we describe the clinical case of an elderly patient with chronic myeloid leukemia and multiple comorbidities (heart disease, diabetes). Following the diagnosis of CML, in 2005 the patient had started treatment with imatinib 400 mg / day; therapy was well tolerated and never suspended until 2011, when he comes to the attention of our center. After re-evaluation of the disease, the patient is considered "failure" according to the recommendations ELN 2009. For this reason he switched to second generation tyrosine kinase inhibitor, nilotinib. After just 3 months of treatment with nilotinib the patient gets a complete cytogenetic response and a reduction of the transcript BCR/ABL %IS from 0,85 to 0,004. These results are still maintained, without any influence on pre-existing conditions.

Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era

2013 ◽  
Vol 13 (7) ◽  
pp. 755-767 ◽  
Author(s):  
Domenico Russo ◽  
Michele Malagola ◽  
Cristina Skert ◽  
Carla Filì ◽  
Cesare Bergonzi ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Elderly Patients ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document